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Abstract
Genetic factors play a role in the etiology of persistent pain conditions, putatively by modulating
underlying processes such as nociceptive sensitivity, psychological well-being, inflammation, and
autonomic response. However, to date, only a few genes have been associated with
temporomandibular disorders (TMD). This study evaluated 358 genes involved in pain processes,
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comparing allelic frequencies between 166 cases with chronic TMD and 1442 controls enrolled in
the OPPERA (Orofacial Pain: Prospective Evaluation and Risk Assessment) study cooperative
agreement. To enhance statistical power, 182 TMD cases and 170 controls from a similar study
were included in the analysis. Genotyping was performed using the Pain Research Panel, an
Affymetrix gene chip representing 3295 single nucleotide polymorphisms, including ancestry-
informative markers that were used to adjust for population stratification. Adjusted associations
between genetic markers and TMD case status were evaluated using logistic regression. The
OPPERA findings provided evidence supporting previously-reported associations between TMD
and two genes: HTR2A and COMT. Other genes were revealed as potential new genetic risk
factors for TMD, including NR3C1, CAMK4, CHRM2, IFRD1, and GRK5. While these findings
need to be replicated in independent cohorts, the genes potentially represent important markers of
risk for TMD and they identify potential targets for therapeutic intervention.
Keywords
Pain genetics; temporomandibular joint disorders (TMD); association study; HTR2A; COMT;
NR3C1; CAMK4; CHRM2; IFRD1; GRK5
Introduction
Temporomandibular disorders (TMD) represent a group of musculoskeletal conditions
characterized by orofacial pain and limitations in function. The etiopathogenesis of TMD is
complex and multifactorial. Proposed risk factors for TMD include joint and muscle trauma,
anatomical factors, psychosocial profile, and sensitization of nociceptive pathways, but the
relative importance of environmental versus genetic factors in explaining variability remains
poorly understood. Although early twin and family studies failed to establish a genetic basis
for the development of TMD,12,25 they had insufficient statistical power to identify genetic
factors for common disorders. Recent work has shown heritable factors play a role in both
experimental pain as well as a wide variety of clinical pain conditions. A number of studies
have estimated substantial heritability in pain disorders related to TMD, such as
fibromyalgia at 51%,24 headache at 34–58%,21,27 and neck pain at 34–52%.11
The multifactorial nature of TMD suggests that a number of distinct genetic loci may play a
role, each contributing small effects that interact with environmental exposures to determine
the course and outcome of the disorder.6 Commonly occurring genetic variants are best
investigated using allelic association methods, in which frequencies of polymorphic genetic
variants are compared between cases and controls.
Candidate gene studies have found several genes to be associated with TMD. The
serotonergic system has received considerable attention, consistent with its known role in
nociceptive and affective pathways. A variable number tandem repeat polymorphism
(VNTR) in the serotonin transporter gene (SLC6A4) has been repeatedly associated with
TMD.13,31 The T102C single nucleotide polymorphism (SNP) of the serotonin receptor
HTR2A has shown evidence of association,28 and allele frequencies in the A218C SNP in
the TPH1 gene, involved in the synthesis of serotonin from tryptophan, have also been
shown to differ between TMD cases and controls.10 Genes related to catecholamine
neurotransmitter pathways have also been associated with TMD. Variants of the gene
encoding the catabolic enzyme catechol-O-methyltransferase (COMT) are associated with
risk of developing TMD,5,37 and intriguingly, differential treatment outcomes.38 Haplotypes
of the beta-2 adrenergic receptor (ADRB2) have also been associated with TMD, and its
psychological and physiological risk markers.6 The greater occurrence of TMD in females
has recently prompted investigators to examine the role of gonadal hormones in disease
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susceptibility. Such studies have replicated an association with estrogen receptor-α (ESR1)
polymorphisms and TMD risk.15,33
This limited group of genes likely represents only the “low-hanging fruit” of genes
contributing to TMD variability, as a growing number of genes have been identified as risk
factors for other common pain conditions;8,17,20 many of these genes have yet to be
examined in TMD subjects.
A primary aim of the OPPERA (Orofacial Pain: Prospective Evaluation and Risk
Assessment) study is to examine the genetic basis of TMD by identifying genetic variants
associated with the odds of chronic TMD and the risk of TMD development. Based on
previous knowledge of chronic pain mechanisms, we hypothesized that the pathogenesis of
TMD may result from disturbances in catecholamine, serotonin, opioid, and cytokine
pathways.1,8 Twenty-three (23) genes belonging to these systems were chosen as candidates
for a genetic association study. This candidate set was expanded with a discovery panel of
over 350 known pain-related genes, to capture novel “TMD genes” previously unrecognized
as risk factors for persistent pain conditions.
Materials and Methods
Study setting and participants
As described elsewhere,[Maixner, overview paper] the OPPERA baseline case-control study
used advertisements, emails, flyers and word-of-mouth to recruit people who had chronic
TMD (“cases”) and people who did not (“controls”). They were recruited between May,
2006 and November, 2008 from communities in and around academic health centers at four
US study sites: Baltimore MD, Buffalo NY, Chapel Hill NC, and Gainesville FL. At each
study site, the target was to recruit 800 controls and variable numbers of cases based on
local operational requirements, for a total of 3,200 controls and 200 cases. The number
enrolled was 3,263 controls and 186 cases.
The classification of TMD was based on the Research Diagnostic Criteria for
Temporomandibular Disorder.9 In summary, cases met all three of the following criteria:
during the telephone interview (i) pain reported with sufficient frequency in the cheeks, jaw
muscles, temples or jaw joints during the preceding six months (at least 15 days in the
preceding month and at least five days per month in each of the five months preceding that);
and during the examination (ii) pain reported in the examiner-defined orofacial region for at
least 5 days out of the prior 30 days; and (iii) pain reported in at least three masticatory
muscles or at least one temporomandibular joint in response to palpation of the orofacial
muscles or maneuver of the jaw. Examiners defined the orofacial region by touching the
following anatomical areas bilaterally: temporalis, preauricular, masseter, posterior
mandibular, and submandibular. Controls met all five of the following criteria: during the
telephone interview (i) pain reported infrequently in the cheeks, jaw muscles, temples or jaw
joints (no orofacial pain in the preceding month and no more than four days per month in
any of the five months preceding that); (ii) no more than four headaches per month within
the preceding three months; (iii) never diagnosed with TMD; (iv) no use of night guard
occlusal splint; and during the examination (v) pain reported in the examiner-defined
orofacial region for no more than 4 days in the prior 30 days. However, controls could be
positive or negative with respect to pain in response to palpation or jaw maneuver. However,
controls could be positive or negative with respect to the examination criteria (iii).
Additional study-wide criteria for all study participants were: aged 18–44 years; fluent in
English; negative responses to each of 10 questions about significant medical conditions; no
history of facial injury or surgery; not receiving orthodontic treatment; not pregnant or
nursing.
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This analysis uses data from all 186 recruited TMD cases and one half of the 3,263 recruited
controls (1,633 people). The controls for this analysis were selected at random so that data
from people in the reserved sample could be used for validation studies that will be reported
elsewhere. The accompanying paper [epi-core paper] gives a more detailed account of study
recruitment, case-classification methods and inclusion and exclusion criteria.
Ethical conduct of research with humans
The OPPERA study was reviewed and approved by institutional review boards at each of
the four study sites and at the data coordinating center, Battelle Memorial Institute. All
participants verbally agreed to a screening interview done by telephone and they provided
informed, signed consent for all other study procedures.
Genotyping
At each OPPERA site, whole blood was collected by venipuncture from study participants
who provided consent for genotyping. Blood was collected into 5mL EDTA containing
polyethylene vacutainers, which were stored at −80°C. Each sample was labeled with a
unique, barcoded identifier label. Genomic DNA was purified utilizing protocols based on
Qiagen Extraction Kits at Cogenics, Inc. (now Beckman-Coulter Genomics, Morrisville,
NC).
Samples were genotyped using the Algynomics (Chapel Hill, NC) Pain Research Panel, a
dedicated chip-based platform utilizing the Affymetrix MegAllele technology. The Pain
Panel assesses 3295 single nucleotide polymorphisms (SNPs) representing 358 genes known
to be involved in systems relevant to pain perception (complete list provided through
http://www.algynomics.com/pain-research-panel.html). Pathways assessed by the Pain Panel
represent one or more of three broad domains and include genes that: (i) mediate the
transmission of pain signals by sensory nerve fibers and by central nervous system neural
pathways that mediate the perception of pain; (ii) mediate peripheral and central
inflammatory responses to tissue injury or psychological stress; (iii) influence mood and
affective states associated with chronic pain conditions. The Panel also includes genes that
influence the pharmacokinetics and dynamics of analgesic compounds and includes
ancestry-informative markers. Within each gene, SNPs were prioritized for inclusion based
on known functionality (i.e., they result in non-synonymous amino acid changes, expression
level differences, or disrupted alternative splicing). Other SNPs were selected as
representative markers of regions with high linkage disequilibrium (LD), containing many
correlated SNPs that are inherited in blocks, in order to “tag” untyped SNPs.
Selected duplicate study samples and HapMap reference DNA were genotyped concurrently
with each batch in order to examine consistency of genotype calls throughout the study, and
genotyping was monitored for batch or site effects in call rates that might introduce bias into
the association tests. All samples were clustered together at the conclusion of the genotyping
process, using the manufacturer’s supplied software in accordance with Affymetrix
protocols. Genotyping results were returned for 3221 unique samples, representing enrollees
in the prospective cohort study and in the case-control study. The overall call rate was
99.1% and repeated sample concordance was 99.8%.
Raw genotypes were filtered for quality using utilities implemented in PLINK v.1.07 (Broad
Institute, Cambridge MA).32 An identity-by-state analysis was performed to cluster
individuals according to racial heritage by multidimensional scaling (MDS) (Supplementary
Fig. 1). Samples were dropped from the study due to: (1) call rate < 0.95 (n=38); (2)
duplicate genotypes (n=20); (3) cryptic relatedness (n=84); (4) mismatch between genotypic
and self-reported sex and race (n=29); and (5) case misclassification (n=14). SNPs were
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filtered for: (1) call rate < 0.95 (n=170); (2) repeated sample concordance rate < 0.99
(n=58); (3) minor allele frequency (MAF) in the full cohort <1% (n=101); and (4) Hardy-
Weinberg equilibrium p-value <1×10−5 in either non-Hispanic whites or African-Americans
separately (n=42).
Statistical Analysis
The final cleaned dataset included 2924 SNPs assayed in 3050 subjects, with a completeness
rate of 99.7%. Baseline data from half of the people enrolled into the prospective cohort
were reserved for later replication studies, leaving 1442 people from the cohort who did not
have TMD when enrolled. Their data were compared to data from the 166 people with
chronic TMD enrolled for the baseline case-control study (Table 1). Chi-square analysis
detected no significant differences between the two split halves in genotyping quality
characteristics.
Association tests assuming codominant effects were performed using logistic regression in
PLINK, in which the number of copies of the rare allele was the genetic predictor variable
and TMD case-status was the dependent variable. As reported in an accompanying paper in
this volume,[Slade et al, EpiCore paper], the percentage of enrollees who were TMD cases
varied among study sites to meet operational requirements: 11% at Baltimore, 6% at
Buffalo, 12% at Chapel Hill and 12% at Gainesville. To account for differences in study
sites, dummy variables coding for the four recruitment sites were introduced as covariates in
the regression model. Also included as covariate terms were sex and the first two
dimensions of variance (eigenvectors) in the MDS analysis, to adjust for population
stratification. After adjustment for study site, age and gender, non-Whites had significantly
lower odds of TMD (OR=0.2, 95%CI = 0.2,0.3) than non-Hispanic Whites. Effect sizes
were estimated using odds ratios (OR) with their corresponding 95% confidence intervals
(CI 95%). To evaluate stratum-specific genetic effects, additional tests were performed as
above in males and females separately (without adjustment for sex), and in Caucasians and
African-Americans separately (without adjustment by racial eigenvectors).
The OPPERA project as originally conceived and powered included a candidate gene study
evaluating 23 strong candidates (see Supplementary e-Table 1 for a list of Tier 1 genes).
Adopting the Pain Research Panel as the genotyping platform provided access to 336
additional known pain-related genes, greatly increasing the exploratory value of the study.
To preserve the intent and power of the original study design, we retained the original, high
priority gene set as a separate “first tier” analysis, and analyzed the full Panel as a second
discovery tier with a more conservative significance threshold.
To maintain a desired experiment-wide α=0.05, it is necessary to correct for the large
number of multiple comparisons in both Tier 1 and Tier 2 phases; this is customarily
performed by applying a Bonferroni correction according to the number of SNPs tested. Due
to LD structure between neighboring SNPs, many of the tested SNPs are correlated and thus
violate the assumption of independent statistical tests, rendering the Bonferroni method
overly conservative. We first calculated the number of effectively independent SNPs in each
tier, taking LD structure into account, by the spectral decomposition method, 23,30 before
applying the Bonferroni correction. The number of independent SNPs in the Tier 1 analysis
was estimated to be 151 (from 211 that passed quality control filters), for a corrected
threshold for significance of p < 3.4×10−4. For the larger Tier 2 SNP set, the number of
effectively independent SNPs was 1911 (of 2657 total), giving a corrected threshold of p <
2.6×10−5.
In order to increase power, subjects from an additional TMD case-control study were added
to the OPPERA cohort. This study was conducted at one of the OPPERA sites (UNC) by
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members of the OPPERA team, with genotyping and phenotyping procedures largely
consistent (and contemporaneous) with OPPERA protocols. Recruitment for the UNC
cohort differed from OPPERA in that all subjects in the UNC cohort were non-Hispanic
white females, aged 18–45; cases were 182 TMD cases recruited through the UNC Orofacial
Pain Clinic (not population-based, as in OPPERA), and controls were 170 healthy women
recruited by community-wide advertisements. After combining studies, the analytical dataset
included 1,961 subjects (348 cases, 1,612 controls), with 2,657 SNPs in common between
cohorts. The linear regression models using the UNC cohort included a covariate term for
this additional study. Secondary analyses assuming dominance and recessive models of
inheritance were performed to characterize genetic effects.
For genes with suggestive single marker associations, multimarker tests were performed
using haplotype analysis. Haplotypes were constructed and phased in PLINK, and statistical
comparison of each identified haplotype with frequency >5% against all others was
performed by logistic regression, adjusted for sex, racial eigenvectors, and site as in the
single SNP analyses.
Results
Quality of genotype data
The genotyping completeness rate in the cleaned dataset approached 99.7% with very strong
correspondence between replicate samples, indicating a high level of confidence in accurate
and unbiased genotyping. OPPERA was designed to be racially inclusive, raising the
possibility that population stratification might lead to systematic allele frequency differences
that could be misinterpreted as association signals. The genomic inflation factor λGC was
calculated as a measure of systematic deviation from the null hypothesis of no association4
for all association tests. Only a minimal elevation of test statistics was detected when
adjusting for site and race in the OPPERA cohort (λGC=1.03) and OPPERA and UNC
combined analyses (λGC=1.00).
TMD Associations
In the analysis of 358 candidate genes (Tier 2 SNP set) using OPPERA cases and controls,
no SNPs exceeded the threshold of statistical significance. The quantile-quantile (Q-Q) plot
of the distribution of p-values did not deviate from that expected under the null hypothesis
(Figure 1). Odds ratios and p-values for the top 20 results are provided in Table 2, for the
full cohort and by sex and racial strata. The majority of SNPs exhibited stronger associations
in females compared to males, but due to the smaller sample size of males it is inconclusive
whether this trend is indicative of sex-specific genetic effects. Similarly, stronger
associations generally were observed in non-Hispanic whites compared with African-
Americans, consistent with the higher numbers of cases and controls in the former group.
The addition of 182 TMD cases and 170 healthy controls from the UNC cohort improved
the resolution of genetic effects, with a number of SNPs elevated above the expected p-value
on the Q-Q plot (Figure 2), although no SNPs exceeded the strict Bonferroni correction
threshold (Figure 3). There were nine SNPs with p-values lower than would be expected by
chance, representing six separate genes (Table 3).
The first three ranked SNPs were located within a 130 kb-long block of high LD within the
glucocorticoid receptor gene NR3C1 on Chr 5. The SNP most strongly associated with
TMD status (rs2963155, minor allele (MA) = G, p = 6.15×10−5, OR = 0.62, 95% CI 0.50–
0.79) was the most common of the three polymorphisms, with a minor allele frequency
(MAF) of 20–24% in both Caucasians and African-Americans (see Table 3 for MAF of
SNPs not given in the text). The next two SNPs were in almost perfect LD with each other
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in Caucasians, with MAF of about 13% (rs9324918, MA = C, p = 8.41×10−5, OR = 0.56,
95% CI 0.42–0.75; and rs33389, MA = T, p = 2.17×10−4, OR = 0.57, 95% CI 0.43–0.77).
The minor alleles of these SNPs all exerted a protective effect against TMD. Conditioning
on rs2963155 eliminated the associations with the other SNPs in the region. These SNPs all
were located within the long intron of the NR3C1 gene and therefore are likely markers of
the true effect polymorphism.
Following the NR3C1 SNPs, the next most strongly associated SNP was an intronic
polymorphism of the serotonin 2A receptor HTR2A (rs9316233, MA = G, p = 3.44×10−4,
OR = 0.64, 95% CI 0.50–0.82). The minor G allele was protective against TMD in our
cohort. A dominant model of inheritance appeared to describe the data better than the
additive model (p = 4.96×10−5, OR = 0.55, 95% CI 0.42–0.74, Supp. Mat. Table 2). In the
analysis of OPPERA subjects, the effect of this SNP was not observed in males. There was
also evidence of a race-specific effect, as the effect was not observed in African-Americans
(OR = 0.90, p = 0.77), in whom the minor allele is almost twice as common as in non-
Hispanic whites (OR = 0.56, p = 0.0053). In white females alone, the protective effect of the
minor G allele was even more evident (OR = 0.39, p = 2.3×10−4).
The next findings were from an intronic SNP in the muscarinic cholinergic receptor 2
(CHRM2) gene with allele counts almost evenly divided between the two alleles
(rs7800170, MA = A, p = 6.20×10−4, OR = 0.72, 95% CI 0.59–0.87). The effect of this SNP
was better modeled by dominance (OR = 0.53, Supp. Mat. Table 2).
The next two SNPs were located in the calcium/calmodulin-dependent protein kinase 4 gene
(CAMK4). The first was found between the second and third exons (rs3756612, MA = G, p
= 6.37×10−4, OR 1.51, 95% CI 1.19–1.92) while the second was located almost 70 kb
downstream between the fifth and sixth exons (rs10491334, MA = T, p = 8.84×10−4, OR =
0.63, 95% CI 0.48–0.83). Although they had similar allele frequencies (about 19% in whites,
5% in African-Americans), they were not in LD and had opposite effects on TMD risk in
our cohort, and therefore represent distinct risk factors (test of allelic interaction p = 0.73).
Again, there was evidence for a dominant model of inheritance for these two SNPs (OR =
1.62 and 0.59, respectively, Supp. Mat. Table 2). Because these two minor alleles did not
coexist in these subjects, haplotype analysis did not provide any additional information.
The risk allele G of the next SNP, located in the first intron of the interferon-related
developmental regulator 1 (IFRD1) gene, was the more common allele in African-
Americans but the less common allele in whites (rs728273, MA = G, p = 0.0012, OR = 1.38,
95% CI 1.13–1.67). In the OPPERA cohort alone, the G allele was weakly associated with
increase in risk for TMD in Caucasians (p = 0.01, OR = 1.42), but no effect was observed in
African-Americans (p = 0.79, OR = 1.11).
The last SNP with suggestive association with TMD was located in the second intron of the
G protein-coupled receptor kinase 5 (GRK5) gene (rs12415832, MA = A, p = 0.0013, OR =
2.40, 95% CI 1.40–4.08). Although uncommon in both races, it was more rare in whites,
with a MAF = 2%. In the OPPERA only analysis stratified by race, the OR was pronounced
in whites (OR = 3.92, p = 2.52×10−4), whereas the association was weak in African-
Americans (OR = 1.51, p = 0.53). To assess whether this result was a statistical limitation of
the regression model, which is sensitive to low MAF, Fisher’s exact test was used because it
is more robust for rare alleles, albeit with no capacity to adjust for covariates. However, the
p-value was very similar (p = 3.05×10−4).
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The 23 genes hypothesized a priori as high priority candidates were intended to mitigate the
stringent Bonferroni correction requirement of correcting for the entire set of SNPs tested.
While no Tier 1 SNPs surpassed the Bonferroni corrected threshold for significance, there
was clear divergence from the p-value distribution expected under the null (Figure 4). Eight
Tier 1 SNPs showed suggestive evidence for association with TMD.
Two SNPs flanking the interleukin 10 (IL10) gene (rs3024496, MA = G, p = 0.0059, OR =
0.76, 95% CI 0.63–0.93; rs1800896, MA = C, p = 0.0086, OR = 0.77, 95% CI 0.64–0.94)
were in strong LD with each other, suggesting they are both markers of a single effect.
Three SNPs tag adrenergic receptor genes: one 12kb upstream from the alpha-2C
(ADRA2C) gene (rs7696139, MA = G, p = 0.0072, OR = 0.74, 95% CI 0.60–0.92), and two
closely spaced within the long intron of the alpha-1D (ADRA1D) gene (rs1556832, MA =
T, p = 0.0082, OR = 1.29, 95% CI 1.07–1.56; rs946188, MA = G, p = 0.018, OR = 0.76,
95% CI 0.61–0.95). Additionally, an intronic SNP in COMT, an enzyme that catabolizes the
catecholamine ligands of these receptors, was also represented among this list (rs174697,
MA = A, p = 0.0099, OR = 1.62, 95% CI 1.12–2.34).
One SNP was located in the long first intron of the delta opioid receptor (OPRD1) gene
(rs2236857, MA = C, p = 0.0087, OR = 1.32, 95% CI 1.07–1.63). The remaining SNP was
located within an intron of the GRIN2A ionotropic N-methyl-D-aspartate (NMDA) receptor
2A gene (rs1448239, MA = C, p = 0.012, OR = 0.71, 95% CI 0.54–0.93).
Discussion
The OPPERA study’s investigation of 358 genes offers opportunities for deeper insight into
the genetic influences on TMD than previous studies that have targeted one or a few genetic
markers. This is, to our knowledge, the first large scale candidate gene study to assess
genetic mediators of TMD in both genders and all races. However, a gene panel of this size
also creates limitations, primarily because of the Bonferroni adjustment of p-value
thresholds which is the conventional method used to adjust for multiple tests. The initial
results reported here describe the effects of individual SNPs on odds of TMD, after
adjustment for potential confounding effects of study site, sex, and race. We also examined
the effect of these SNPs across strata, as a major goal of OPPERA is to discover how these
variables interact. In general, though, this stratification decreased statistical power compared
to analysis of the complete sample, with the result that no SNPs achieved a strict
experiment-wide significance threshold. However, we believe that the evidence of
association of the top associated SNPs is strong enough to warrant further study and
replication of these genes in other cohorts. The OPPERA investigative group is also
currently expanding the number of TMD cases in order to perform a genome-wide
association study. This approach will further improve statistical power and provide for
unbiased assessment of the genetic contribution to TMD.
We observed association with TMD in a number of genes previously shown to influence
TMD risk. The strongest such association was for rs9316233 of the HTR2A serotonin
receptor gene, where the minor G allele showed a protective effect against TMD risk. This
gene was previously associated with TMD based on another of its SNPs, rs6313, a
synonymous polymorphism in the first exon of the gene.28 It lies 40kb upstream from
rs9316233, and is not in strong LD with it (D′ = 0.29, r2 = 0.02). A tag SNP in strong LD
with rs6313 was also assessed in this study (rs4941573, r2 = 1.0); the G allele corresponding
to the protective T allele in rs6313 showed a trend toward greater risk (recessive test OR =
1.34, p = 0.11). More recently, two other SNPs in the HTR2A gene were associated with
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chronic widespread musculoskeletal pain in a prospective, population-based cohort study.29
These SNPs were not genotyped or tagged at r2 > 0.80 in the present study, and are not in
LD with rs9316233 (r2 < 0.02 for both SNPs). The risk variant discovered in this study is
therefore not a replication of the earlier HTR2A findings, but rather represents a novel
genetic risk factor.
We observed a suggestive association at a SNP in the COMT locus, rs174697. Previous
reports have not tested its association with any pain phenotype. Diatchenko et al.5 described
three common haplotypes of COMT that predict low (LPS), average (APS), or high (HPS)
pain sensitivity in white females. Consistent with the previous finding, in this study the HPS
haplotype was significantly associated with a higher risk of TMD (OR = 1.28, one-sided test
p = 0.05) relative to the other haplotypes, although there was no significant difference
between the APS and LPS haplotypes. The effect of rs174697 is independent of these
haplotypes, which suggests that the haplotypic diversity of this gene is more complex than
previously reported, although an effect of this SNP is consistent with an additional
functional site at the 3′ end of the COMT gene locus.34,35
Several genes selected as Tier 1 candidates showed associations that were stronger than
expected by chance, and will be useful in OPPERA’s additional studies of TMD onset.
Evidence continues to accrue supporting a role for monoamine pathways in TMD
susceptibility. Previously we observed suggestive associations between TMD and adrenergic
receptors ADRA2A and ADRA1D as well as COMT. These results are consistent with the
crucial role of catecholamines in persistent pain and chronic musculoskeletal pain
conditions.3,5,22,39
Furthermore, our data suggest that genetic variations in OPRD1 16,26 and GRIN2A genes
play a role in TMD development. Functional polymorphisms in these genes may result in
disturbance of pain regulatory pathways, underlying a state of pain amplification leading to
the development of persistent pain and thus contributing to TMD.7 Similarly, alterations in
the anti-inflammatory activity of IL10 may cause people to respond differently to trauma or
stress.36
This study revealed a number of genes which, while known to be involved in nociceptive
pathways, have not been shown previously to be involved in susceptibility to a chronic pain
condition. These genes warrant further investigation as mediators of TMD risk and as
potential targets for therapeutic intervention.
The glucocorticoid receptor encoded by the NR3C1 gene is the binding site for cortisol and
a major element of the hypothalamic-pituitary-adrenal (HPA) system. The HPA system is
the primary endocrine stress axis in humans and has been implicated in the pathophysiologic
development of TMD.19 NR3C1 has been investigated, along with several other HPA axis
genes, for association with somatic symptom count in a large population-based study, but no
associations were discovered in this gene.14
Comparatively little data exist linking CHRM2, CAMK4, IFRD1, and GRK5 to nociception.
CHRM2 codes for muscarinic cholinergic receptor 2 that binds to acetylcholine and controls
cellular responses such as adenylate cyclase inhibition, phosphoinositide degeneration, and
potassium channel mediation in the central and peripheral nervous system. The other
candidate genes code for regulatory proteins. The CAMK4 gene codes for a multifunctional
serine/threonine protein kinase with limited tissue distribution that has been implicated in
transcriptional regulation in neurons. Its activity affects learning and memory,42 and
development of opioid analgesic tolerance.18 IFRD1 is a histone-deacetylase-dependent
transcriptional co-regulator and is involved in control of inflammation, the growth and
differentiation of specific cell types during embryonic development, and tissue regeneration.
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Mutations in this gene are associated with sensory/motor neuropathy with ataxia.2 GRK5 is
involved in the phosphorylation and regulation of activation of G protein-coupled receptors,
including several that have been implicated in chronic pain, including ADRB2.40,41
Although several compelling genetic risk factors were revealed in this study, it will be
necessary to confirm putative associations in independent cohorts. The power of this study
was limited for several reasons. The number of cases in this study, even with the addition of
the UNC cohort, was small relative to the number of controls, and to the number that would
be needed to achieve the desired power. As implemented, this study had only 25% power to
detect even the larger odds ratios observed (>1.4) for a SNP with a median MAF of 0.25.
Therefore, it is possible that we failed to detect additional genes with true effects on TMD
risk, and it is also likely that the observed effect sizes of the top associated SNPs are inflated
over their true values, due to the “winner’s curse” phenomenon.43 Heterogeneity in the
subject population, while a valuable property for the epidemiological goals of the OPPERA
project, likely impeded our ability to parse subtle genetic effects. This heterogeneity arose
both from the racially inclusive recruitment, but also from the different sources which
provided cases (population-based for OPPERA, pain clinic-based for UNC).
The OPPERA study offers considerable potential to investigate combined effects of
genotypes and a rich set of baseline intermediate phenotypes, including clinical,
psychosocial, autonomic, and sensory domains. In addition, data on first onset TMD from
the OPPERA prospective cohort study will be analyzed to search for genes that predict onset
of TMD after the five years of follow-up.
In summary, the OPPERA case-control study is the first genetic association study of TMD
to have investigated a substantial number of pain related candidate genes. While the results
require replication, they provide tentative evidence that chronic TMD is influenced by
genetic contributions within a number of gene loci, including NR3C1, CAMK4, CHRM2,
IFRD1, GRK5, HTR2A and COMT.
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Refer to Web version on PubMed Central for supplementary material.
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Genetic risk factors for TMD pain were explored in the case-control component of the
OPPERA cooperative agreement, a large population based prospective cohort study.
Over 350 candidate pain genes were assessed using a candidate gene panel, with several
genes displaying preliminary evidence for association with TMD status.
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Genetic Association Test for 358 candidate genes from 166 TMD cases and 1442 controls in
the OPPERA study
Q-Q plot of case-control association test within OPPERA cohort only. Each blue dot
represents a single SNP. The observed −log10(p-values) on the y-axis are ranked and plotted
against the expected −log10(p-values) under the null hypothesis on the x-axis; the null
distribution is represented by the red line. Since no SNP elevated significantly above the
expected line, we were not able to reject the null hypothesis for SNPs with −log10(p-values).
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Genetic Association Test for 358 candidate genes from 348 TMD cases and 1612 controls in
the combined OPPERA and UNC studies
Q-Q plot of case-control association test within combined OPPERA and UNC cohorts. Each
blue dot represents a single SNP. The observed −log10(p-values) on the y-axis are ranked
and plotted against the expected −log10(p-values) under the null hypothesis on the x-axis;
the null distribution is represented by the red line. Eleven SNPs showed elevation above the
expected line, thus rejecting the null hypothesis for SNPs with −log10(p-values).
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Manhattan Plot of Genetic Association Test for 358 candidate genes from 348 TMD cases
and 1612 controls in the combined OPPERA and UNC studies
Each dot represents a single SNP, mapped by genomic location on the x-axis and the
observed −log10(p-values) on the y-axis. Each chromosome is colored differently.
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Genetic Association Test for Tier 1 SNPs in 23 candidate genes from 348 TMD cases and
1612 controls in the combined OPPERA and UNC studies
Q-Q plot of case-control association test within combined OPPERA and UNC cohorts for
Tier 1 genes. Each blue dot represents a single SNP. The observed −log10(p-values) on the
y-axis are ranked and plotted against the expected −log10(p-values) under the null
hypothesis on the x-axis; the null distribution is represented by the red line. Eight SNP
showed elevation above the expected line, thus rejecting the null hypothesis for SNPs with
−log10(p-values).
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Caucasian Male 24 308 332
Female 103 423 526
All 127 731 858
African-American Male 3 183 186
Female 16 236 252
All 19 419 439
Other/Mixed Male 1 144 145
Female 19 148 167
All 20 292 312
All Male 28 635 663
Female 138 807 945
All 166 1442 1608
Numbers of subjects used for genetic association, stratified by racial background, sex, and case status.
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